Sol-Gel Technologies (SLGL) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sol-Gel Technologies has struck six exclusive licensing deals to market their dermatology products TWYNEO and EPSOLAY in most European countries and South Africa, with financials involving upfront and milestone payments up to low 7-digit USD figures, alongside future sales royalties. These agreements, which include commitments to minimum annual sales, build on Sol-Gel’s existing partnerships in the US, Canada, and China, showcasing the growing global confidence in their products. The company continues to advance its clinical trials for other potential treatments, further strengthening its competitive position in the dermatology pharmaceutical market.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.